The Matrix model of outpatient stimulant abuse treatment: evidence of efficacy

UCLA Department of Psychiatry, USA.
Journal of Addictive Diseases (Impact Factor: 1.46). 02/1994; 13(4):129-41.
Source: PubMed


The current study examined the effectiveness of Matrix outpatient stimulant treatment. We associated 146 subjects' in-treatment abstinence data, treatment lengths, and weekly treatment activities to their 6-month abstinence outcomes as part of an interim analysis of a NIDA treatment demonstration project. Results indicated that the pretreatment subject characteristics of ethnicity and drug of choice significantly associated with treatment outcome using Matrix model treatment. Findings also demonstrated a treatment dose/abstinence response such that those who received longer Matrix treatment episodes demonstrated better abstinence outcomes. Further, in-treatment abstinence status and treatment length significantly associated with drug use status at follow-up. This set of findings provides evidence for the value of Matrix treatment and allows for these outcome data to be compared with reports on recent psychosocial treatments for stimulant dependence. This study also provides direction for evaluating longer term effectiveness for these types of drug treatments.

1 Follower
39 Reads
  • Source
    • "To our knowledge, there have been limited examples, if any, of studies that have documented the implementation of evidence-based substance abuse treatment in aresource-limited setting in Sub-Saharan Africa, where many structural barriers to treatment exist and there are limited options for evidence-based care[15,16]. This Matrix site provides treatment in an area of SA with high rates of polysubstance use and one of the highest rates of methamphetamine use in the world[10].Note: Dependent variable (treatment completion) was coded as 0 = less than 16 weeks 1 = greater than 16 weeks. ASSIST and SOCRATES scores were mean centered for ease of interpretation. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Aims: This study documented the treatment cascade for engagement in care and abstinence at treatment exit as well as examined correlates of these outcomes for the first certified Matrix ModelĀ® substance abuse treatment site in Sub-Saharan Africa. Design: This retrospective chart review conducted at a resource-limited community clinic in Cape Town, South Africa, assessed treatment readiness and substance use severity at treatment entry as correlates of the number of sessions attended and biologically confirmed abstinence at treatment exit among 986 clients who initiated treatment from 2009-2014. Sociodemographic and clinical correlates of treatment outcomes were examined using logistic regression, modeling treatment completion and abstinence at treatment exit separately. Results: Of the 2,233 clients who completed screening, approximately 44% (n = 986) initiated treatment. Among those who initiated treatment, 45% completed at least four group sessions, 30% completed early recovery skills training (i.e., at least eight group sessions), and 13% completed the full 16-week program. Approximately half (54%) of clients who provided a urine sample had negative urine toxicology results for any substance at treatment exit. Higher motivation at treatment entry was independently associated with greater odds of treatment completion and negative urine toxicology results at treatment exit. Conclusions: Findings provide initial support for the successful implementation the Matrix Model in a resource-limited setting. Motivational enhancement interventions could support treatment initiation, promote sustained engagement in treatment, and achieve better treatment outcomes.
    Full-text · Article · Jan 2016 · PLoS ONE
  • Source
    • "Methamphetamine dependence directly or indirectly affects millions of Americans, and despite the efficacy of current treatments for some patients, relapse remains a significant problem (Huber et al, 1997; Rawson et al, 1999, 2004; Shoptaw et al, 1994). These studies, along with many others, underscore the challenge inherent in providing effective treatment to methamphetamine users. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Bupropion is an antidepressant with stimulant properties, which inhibits the reuptake of dopamine (DA) and norepinepherine, and is purported to enhance DA neurotransmission. Bupropion is considered an appealing candidate medication for the treatment of methamphetamine dependence. The current laboratory study was set forth to assess the impact of bupropion treatment on the subjective effects produced by methamphetamine in the laboratory. We also assessed the effects of bupropion treatment on craving elicited by exposure to videotaped methamphetamine cues. A total of 26 participants were enrolled and 20 completed the entire study (n=10 placebo and n=10 bupropion, parallel groups design). Bupropion treatment was associated with reduced ratings of 'any drug effect' (p<0.02), and 'high' (p<0.02) following methamphetamine administration. There was also a significant bupropion-by-cue exposure interaction on General Craving Scale total score (p<0.002), and on the Behavioral Intention subscale (p<0.001). Overall, the data reveal that bupropion reduced acute methamphetamine-induced subjective effects and reduced cue-induced craving. Importantly, these data provide a rationale for the evaluation of bupropion in the treatment of methamphetamine dependence.
    Full-text · Article · Jul 2006 · Neuropsychopharmacology
  • Source
    • "Content of the treatment program is tailored to individual needs, although basic program elements are structured and manualized. Previous results from a number of open trials using the Matrix approach have been published in the research literature (Huber et al., 1997; Rawson et al., 1995; Rawson, Huber, et al., 2002; Shoptaw et al., 1994). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Methamphetamine (MA) is a major public health and criminal justice problem in much of the Western and Midwestern US, and its use seems to be increasing east of the Mississippi River. MA use can produce significant psychiatric and medical consequences, including psychosis, dependence, overdose, and death. Cognitive behavioral therapy and contingency management are among the most promising approaches for treatment of MA abuse and dependence. A multisite study evaluating the Matrix Model of outpatient treatment will soon be completed to provide data on this manualized approach. An ambitious program of pharmacotherapy development research is currently being sponsored by the National Institute on Drug Abuse (NIDA) in geographic areas significantly affected by MA use. The development of treatments for MA-related problems is particularly critical for a number of user groups including MA users who experience persistent psychosis, pregnant women and women with children, gay and bisexual men, and MA users involved in the criminal justice system.
    Preview · Article · Oct 2002 · Journal of Substance Abuse Treatment
Show more